AG (FSE:MF6) announced today the publication of clinical data from a clinical
study examining the safety and efficacy of intratumoral thermotherapy using
magnetic iron-oxide nanoparticles combined with external beam radiotherapy in
patients with recurrent glioblastoma multiforme.
The study data, published on September 20, 2010 in the Journal of Neuro-Oncology,
is available online on the Journal's website at
"This data publication provides detailed insight into the clinical data
our recent regulatory approval for Nano-CancerÒ therapy. Through the
publication, we are
pleased to address a wider international audience and give them insight into
novel concept of using nanotechnology for the treatment of cancer," said
Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused
strengthening our commercialization team and infrastructures in preparation
for the next
strategic steps, including the planned Q1 2011 product launch in Germany, additional
clinical trials, and further internationalization."
Nano-Cancer therapy uses iron oxide nanoparticles, which are injected into
the tumor and, due to their special coating, aggregate and remain in place.
The patient is then placed into a magnetic field applicator. Through the application
of an alternating magnetic field, the nanoparticles begin to oscillate, produce
warmth, and damage or kill the tumor tissue.
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based
cancer treatment. The proprietary procedure which it has developed, Nano-Cancer
therapy, enables the targeted treatment of solid tumors through the intratumoral
release of heat from magnetic nanoparticles. Its products used in the therapy,
NanoTherm and NanoActivator, have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors.